Disappointing early sales results for its newest treatments, Rhopressa and Rocklatan, haven't shaken the company's confidence. Wall Street is a different story.
News & Analysis: Aerie Pharmaceuticals
Slow sales of its glaucoma drugs is forcing management to cut its sales guidance.
AERI earnings call for the period ending September 30, 2019.
The small-cap company's shares have fallen 64% in the last year, but a promising drug portfolio might signal an opportunity for investors with a long-term mindset.
A new slide deck shows reasons for optimism.
AERI earnings call for the period ending June 30, 2019.
AERI earnings call for the period ending March 31, 2019.
AERI earnings call for the period ending December 31, 2018.
The company's establishing itself as a leader in this growing, multibillion-dollar indication.
The company's glaucoma treatment has gotten the regulatory green light, but can it live up to lofty expectations?